Time-Dose Relationships for 5-Fluorouracil Cytotoxicity against Human Epithelial Cancer Cells in Vitro

Cancer Research

Volumn 42, Issue 11, 1982, Pages 4413-4420

  Calabro Jones, Paula M ^a,b   Ward, John F ^a   Bvfield, John E ^b   Sharp, Thomas R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

CANCER CELL; CARCINOMA; CELL CULTURE; COLON CANCER; COLON CARCINOMA; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENDOCRINE SYSTEM; FEMALE GENITAL SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; INTOXICATION; LARGE INTESTINE; OVARY CARCINOMA; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; CELL LINE; CELL SURVIVAL; CERVIX NEOPLASMS; CLONE CELLS; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMAN; KINETICS; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0020352728     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Ansfield, F. J. Chemotherapy of Malignant Neoplasms. Springfield, III.: Charles C Thomas, Publishers, 1973.
2. Barone, R. M., Byfield, J. E., and Frankel, S. Combination infusional 5-FU and radiation therapy for the treatment of metastatic carcinoma of the colon to the liver. Dis. Colon Rectum, 22: 376–382, 1979.
3. Barone, R. M., Calabro-Jones, P., Thomas, T. N., Sharp, T. R., and Byfield, J. E. Surgical adjuvant therapy in colon carcinoma: a human tumor spheroid model for evaluating radiation sensitizing agents. Cancer (Phila.), 47:2349–2367, 1981.
4. Byfield, J. E., Barone, R. M., Calabro-Jones, P., Lin, C., Murnane, J. P., and Ward, J. F. A human tumor spheroid model for evaluating agents active against hypoxic cells, In: L. W. Brady (ed.), Cancer Management: Radiation Sensitizers, Vol. 5, pp. 465–471. New York: Masson Publishing, USA, Inc., 1980.
5. Byfield, J. E., Barone, R., Mendelsohn, J., Frankel, S., Quinol, L., Sharp, T., and Seagren, S. Infusional 5-fluorouracil and X-ray therapy for nonresecta-ble esophageal cancer. Cancer (Phila.), 45: 703–708, 1980.
6. Byfield, J. E., Calabro-Jones, P., Klisak, I., and Kulhanian, F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-FU or ftorafur and X-rays. Int. J. Radiat. Oncol. Biol. Phys., 8: In press, 1982.
7. Byfield, J. E., Murnane, J. P., Ward, J. F., Calabro-Jones. P., Lynch, M., and Kulhanian. F. Mice, men, mustards, and the methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumors to alkylating agents. Br. J. Cancer, 43: 669–683, 1981.
8. Byfield, J. E., Stanton, W., Frankel, S. S., and Sharp, T. R. Phase I—II trial of Infused 5-fluorouracil (I-5FU) and split-course X-ray therapy in nonresecta-ble (stage III) non-oat cell lung cancer (NOLCa). Proc. Am. Assoc. Cancer Res., 22: 507, 1981.
9. Clarkson, B., O’Conner, A., Winston, L., and Hutchison, D. The physiologic disposition of 5-fluorouracil and 5-fluoro-2'-deoxyuridine in man. Clin. Pharmacol. Ther., 5: 581–610, 1968.
10. Cohen, J. I., Irwin, L. E., Marshall, G. J., Darvey, H., and Bateman, J. R. Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893). Cancer Chemother. Rep. Part I, 58: 723–731, 1974.
11. DiSaia, P. J., Sinkovics, J. G., Rutledge, F. N., and Smith, J. P. Cell-mediated Immunity to human malignant cells. Am. J. Obstet. Gynecol., 114: 979–989, 1972.
12. Drewinko, B., Romsdahl, M. M., Yang, L. Y., Aheam, M. J., and Trujillo, J. M. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res., 36: 467–475, 1976.
13. Drewinko, B., Yang, L. Y., Ho, D. H. W., Benvenuto, J., Loo, T. I., and Freireich, E. J. Treatment of cultured human colon carcinoma cells with fluorinated pyrimidines. Cancer (Phila.), 45: 1144–1158, 1980.
14. Evans, R. M., Laskin, J. D., and Hakala, M. T. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res., 40: 4113–4122, 1980.
15. Floyd, R., Griffiths, J., Hombeck, C., Frankel, S., Sharp, T. and Byfield, J. E. Total body clearance of infusional 5-fluorouracil (5-FU). Proc. Am. Assoc. Cancer Res., 21: 395, 1980.
16. Fraile, R. J., Baker, L. H., Buroker, T. R., Horwitz, J., and Vaitkevicius, V. K. Pharrnacokinetics of 5-fluorouracil adminstered orally, by rapid intravenous and by slow infusion. Cancer Res., 40: 2223–2228, 1980.
17. Fukushima, M., Ikenaka, K., Shirasaka, T., and Fujii, S. Metabolism of 5-fluorouracil in sensitive and resistant tumor cells. Gann, 70: 47–53, 1979.
18. Heidelberger, C. Fluorinated pyrimidines. Prog. Nucleic Acid Res. Mol. Biol., 4: 2–50, 1965.
19. Heidelberger, C., Chaudhuri, N. K., Danneberg, P., Moore, D., Greisbach, L., Dushinsky, R., Schnitzer, R. J., Pleven, E., and Scheiner, J. Fluorinated pyrimidines, a new class of tumor-inhibiting compounds. Nature (Lond.), 179: 663–666, 1957.
20. Hillcoat, B. L., McCulloch, P. B., Figueredo, A. T., Ehsan, M. M., and Rosenfeld, J. M. Clinical response and plasma levels of 5-fluorouracil in patients with colon cancer treated by drug infusion. Br. J. Cancer 58: 719–724, 1978.
21. Hombeck, C. L., Floyd, R. A., Griffiths, J. C., and Byfield, J. E. Improved liquid chromatographic assay for serum fluorouracil concentrations in the presence of ftorafur. J. Pharm. Sci., 70: 1163–1166, 1981.
22. Horton, J., Hacker, B., Cunningham, T. J., and Sponzo, R. W. The chemotherapy of large bowel cancer. Present status and future prospects. Dig. Dis. Sci., 19: 1040–1046, 1974.
23. Houghton, J. A., Houghton, P. J., and Wooten, R. S. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res., 39: 2406–2413, 1979.
24. Laskin, J. D., Evans, R. M. Slocum, H. K., Burke, D., and Hakala, M. Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res., 39: 383–390, 1979.
25. Looney, W. B., Hopkins, H. A., MacLeod, M. S., and Ritenour, R. Solid tumor models for the assessment of different treatment modalities. XII. Combined chemotherapy-radiotherapy: variation of time interval between time of administration of 5-fluorouracil and radiation and its effect on the control of tumor growth. Cancer (Phila.), 44: 437–445, 1979.
26. Looney, W. B., Schaffner, J. G., Trefil, J. S., Kovacs, C. J., and Hopkins, H. A. Solid tumor models for the assessment of different treatment modalities. IV. The combined effects of radiation and 5-fluorouracil. Br. J. Cancer, 34: 254–261, 1976.
27. Looney, W. B., Trefil, J. S., Hopkins, H. A., Kovacs, C. J., Ritenour, R., and Schaffner, J. G. Solid tumor models for assessment of different treatment modalities: therapeutic strategy for sequential chemotherapy with radiotherapy. Proc. Natl. Acad. Sci. U. S. A., 74: 1983–1987, 1977.
28. MacMillan, W. E., Wolberg, W. H., and Welling, P. G. Pharmacokinetics of fluorouracil in humans. Cancer Res., 38: 3479–3482, 1978.
29. Madoc-Jones, H., and Bruce, W. R. On the mechanism of the lethal action of 5-fluorouracil on mouse L cells. Cancer Res., 28: 1976–1981, 1968.
30. Maybaum, J., Ullman, B., Mandel, H. G., Day, J. L., and Sadee, W. Regulation of RNA and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res., 40: 4209–4215, 1980.
31. Moertel, C. G. Clinical management of advanced gastrointestinal cancer. Cancer (Phila.) 36: 675–682, 1975.
32. Moertel, C. G. Current concepts in cancer. Chemotherapy of gastrointestinal cancer. N. Engl. J. Med., 299: 1049–1052, 1978.
33. Murnane, J. P., Byfield, J. E., Ward, J. F., and Calabro-Jones, P. Effects of methylated xanthines on mammalian cells treated with bifunctional alkylating agents. Nature (Lond.), 285: 326–329, 1980.
34. Myers, C. E., Diasio, R., Eliot, H. M., and Chabner, B. A. Pharmacokinetics of the fluoropyrimidines: implications for their clinical use. Cancer Treat. Rev., 3: 175–183, 1976.
35. Myers, C. E., Young, R. C., and Chabner, B. A. Biochemical determinants of 5-fluorouracil response in vivo: the role of deoxyuridylate pool expansion. J. Clin. Invest., 56: 1231–1238, 1975.
36. Roper, P. R., and Drewinko, B. Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res., 36: 2182–2188, 1976.
37. Schaer, J. C., Maurer, V., and Schindler, R. Determination of thymidine in serum used for cell culture media. Exp. Cell Biol. 46: 1–10, 1978.
38. Schein, P. S., Kisner, D., and MacDonald, J. S. Chemotherapy of large Intestinal cancer. Current results and future prospects. Cancer (Phila.), 43: 2181–2188, 1979.
39. Schwartz, P. M., and Handschumacher, R. E. Selective antagonism of 5-fluorouracil cytotoxicity by 4-hydroxypyrazolopyrimidine (allopurinol) in vitro. Cancer Res., 39: 3095–3101, 1979.
40. Seifert, P., Baker, L. H., Reed, M. L., and Vaitkevicius, V. K. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal carcinoma. Cancer (Phila.), 36: 123–128, 1975.
41. Semple, T. U., Quinn, L. A., Woods, L. K., and Moore, G. E. Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model. Cancer Res. 38: 1345–1355, 1978.
42. Sitar, D. S., Shaw, D. H., Thiriwell, M. P., and Ruedy, J. R. Disposition of 5-fluorouracil after intravenous bolus doses of a commercial formulation to cancer patients. Cancer Res., 37: 3981–3984, 1977.
43. Stragand, J. J., Bergerat, J., White, R. A., Hokanson, J., and Drewinko, B. Biological and cell kinetic properties of a human colonic adenocarcinoma (LoVo) grown in athymic mice. Cancer Res., 40: 2846–2852, 1980.
44. Sykes, J. A., Whitescarver, J., Nolan, J. T., and Jernstrom, P. Preliminary studies of a new epithelioid cell line of human origin. In Vitro (Rockville), 6: 217–218, 1970.
45. Tseng, W., Medina, D., and Randerath, K. Specific inhibition of transfer RNA methylation arid modification in tissues of mice treated with 5-fluorouracil. Cancer Res., 38: 1250–1257, 1978.
46. Vaitkevicius, V. K., Baker, L. H., Buroker, T. R., Kim, P. N., and Reed, M. L. Chemotherapy of gastrointestinal adenocarcinoma In: Cancer Chemotherapy: Fundamental Concepts and Recent Advances, Nineteenth Annual Clinical Conference on Cancer, M. D. Anderson Hospital, pp. 263–278. Chicago: YearBook Medical Publishers, Inc., 1975.